Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.3 USD | -3.31% | -4.43% | -15.42% |
20/05 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
14/05 | Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.42% | 611.71Cr | |
+10.51% | 12TCr | |
+12.16% | 11TCr | |
-4.56% | 2.47TCr | |
-2.33% | 2.2TCr | |
-6.03% | 1.93TCr | |
-13.45% | 1.76TCr | |
-40.50% | 1.73TCr | |
+6.05% | 1.4TCr | |
+30.58% | 1.21TCr |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Exelixis Investor Farallon Capital Plans to Nominate Three New Independent Directors to Board, Cites Strategy Concerns